肿瘤细胞治疗研究
英文原题：Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.
Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
B 细胞成熟抗原（BCMA）靶向免疫治疗在复发/难治性（R/R）多发性骨髓瘤（MM）的治疗中显示出前所未有的结果。
B 细胞成熟抗原（BCMA）靶向免疫治疗在复发/难治性（R/R）多发性骨髓瘤（MM）的治疗中显示出前所未有的结果。然而，疾病进展仍然是一个问题，归因于 MM 中 BCMA 表达可变、BCMA 下调以及肿瘤抗原异质性。因此，需要具有新治疗靶点的额外治疗选择。G 蛋白偶联受体 C 类第 5 组成员 D（GPRC5D）是一种在恶性浆细胞上表达、在正常组织中表达有限的孤儿受体，已成为 R/R MM 有前景的治疗靶点。GPRC5D 靶向嵌合抗原受体（CAR）-T 和 CAR-NK 细胞疗法，以及双特异性 T 细胞衔接器，提供了显著的抗肿瘤活性。我们总结了 2022 ASH 年会（ASH 2022）上关于 GPRC5D 靶向治疗 R/R MM 的一些最新报告。
B cell maturation antigen (BCMA)-targeted immunotherapy has shown unprecedented results in the treatment of relapsed or refractory (R/R) multiple myeloma (MM). However, disease progression remains an issue attributed to variable BCMA expression, BCMA downregulation, and heterogeneity of tumor antigens in MM. Therefore, additional treatment options with novel therapeutic targets are warranted. G protein-coupled receptor, class C group 5 member D (GPRC5D), an orphan receptor expressed on malignant plasma cells with limited expression in normal tissue, has emerged as a promising therapeutic target for R/R MM. GPRC5D-targeted chimeric antigen receptor (CAR)-T and CAR-NK cell therapy, as well as bispecific T cell engagers, offer remarkable anti-tumor activities. We summarized some latest reports on GPRC5D-targeted treatments for R/R MM from the 2022 ASH Annual Meeting (ASH 2022).
MEMBER ACCOUNT
登录成功会直接打开下一页。
